In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies.
Allott EH, Craig EL, Stopsack KH.
Prostate Cancer Prostatic Dis. 2021 Mar 29. PMID: 33782544
Links
Bibliography
Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?
Stopsack KH.
Eur Urol. 2021 Apr. 79(4):453-455. PMID: 33551298
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells.
Pan W, Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, Lee GM, Choueiri TK, Kantoff PW.
Clin Cancer Res. 2021 Apr 01. 27(7):2087-2099. PMID: 33495313
Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Stopsack KH.
Eur Urol. 2021 Mar. 79(3):e81-e82. PMID: 33358233
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW.
Clin Cancer Res. 2021 Mar 15. 27(6):1792-1806. PMID: 33334906
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E.
Nat Genet. 2020 11. 52(11):1219-1226. PMID: 33106634
Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.
Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Wu L, Jacobs EJ, Mucci LA, Platz EA, Cook MB.
J Natl Cancer Inst. 2020 Oct 03. PMID: 33010161
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M.
Clin Cancer Res. 2020 Nov 15. 26(22):5903-5913. PMID: 32913135